Head-to-Head Comparison of the in Vivo Performance of Highly Reactive and Polar 18F-Labeled Tetrazines

IF 4.5 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Lars Hvass*, Marius Müller, Markus Staudt, Rocio García-Vázquez, Tobias K. Gustavsson, Vladimir Shalgunov, Jesper T. Jørgensen, Umberto M. Battisti*, Matthias M. Herth* and Andreas Kjaer*, 
{"title":"Head-to-Head Comparison of the in Vivo Performance of Highly Reactive and Polar 18F-Labeled Tetrazines","authors":"Lars Hvass*,&nbsp;Marius Müller,&nbsp;Markus Staudt,&nbsp;Rocio García-Vázquez,&nbsp;Tobias K. Gustavsson,&nbsp;Vladimir Shalgunov,&nbsp;Jesper T. Jørgensen,&nbsp;Umberto M. Battisti*,&nbsp;Matthias M. Herth* and Andreas Kjaer*,&nbsp;","doi":"10.1021/acs.molpharmaceut.4c0112910.1021/acs.molpharmaceut.4c01129","DOIUrl":null,"url":null,"abstract":"<p >Pretargeted imaging harnessing tetrazine ligation has gained increased interest over recent years. Targeting vectors with slow pharmacokinetics may be visualized using short-lived radionuclides, such as fluorine-18 (<sup>18</sup>F) for positron emission tomography (PET), and result in improved target-to-background ratios compared to conventionally radiolabeled slowly accumulating vectors. We recently developed different radiochemical protocols enabling the direct radiofluorination of various tetrazine scaffolds, resulting in the development of various highly reactive and polar <sup>18</sup>F-labeled tetrazines as lead candidates for pretargeted imaging. Here, we performed a direct head-to-head-comparison of our lead candidates to evaluate the most promising for future clinical translation. For that, all <sup>18</sup>F-labeled tetrazine-scaffolds were synthesized in similar molar activity for improved comparability of their <i>in vivo</i> pretargeting performance. Intriguingly, previously reported dicarboxylic acid lead candidates with a net charge of −1 were outperformed by respective monocarboxylic acid derivatives bearing a net charge of 0, warranting further evaluation of such scaffolds prior to their clinical translation.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"22 4","pages":"1911–1919 1911–1919"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acs.molpharmaceut.4c01129","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.4c01129","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Pretargeted imaging harnessing tetrazine ligation has gained increased interest over recent years. Targeting vectors with slow pharmacokinetics may be visualized using short-lived radionuclides, such as fluorine-18 (18F) for positron emission tomography (PET), and result in improved target-to-background ratios compared to conventionally radiolabeled slowly accumulating vectors. We recently developed different radiochemical protocols enabling the direct radiofluorination of various tetrazine scaffolds, resulting in the development of various highly reactive and polar 18F-labeled tetrazines as lead candidates for pretargeted imaging. Here, we performed a direct head-to-head-comparison of our lead candidates to evaluate the most promising for future clinical translation. For that, all 18F-labeled tetrazine-scaffolds were synthesized in similar molar activity for improved comparability of their in vivo pretargeting performance. Intriguingly, previously reported dicarboxylic acid lead candidates with a net charge of −1 were outperformed by respective monocarboxylic acid derivatives bearing a net charge of 0, warranting further evaluation of such scaffolds prior to their clinical translation.

近年来,利用四嗪结扎进行靶前成像越来越受到关注。使用短寿命放射性核素(如用于正电子发射断层扫描(PET)的氟-18 (18F))可以对药代动力学缓慢的靶向载体进行可视化,与传统的放射性标记缓慢蓄积载体相比,靶-背景比得到了改善。我们最近开发出了不同的放射化学方案,可以直接对各种四嗪支架进行放射性氟化,从而开发出了各种高活性和极性的 18F 标记四嗪,作为预靶向成像的先导候选物。在这里,我们对候选先导化合物进行了直接的正面比较,以评估最有希望在未来实现临床转化的化合物。为此,我们以相似的摩尔活性合成了所有 18F 标记的四嗪affolds,以提高其体内预靶向性能的可比性。耐人寻味的是,之前报道过的净电荷为-1的二羧酸先导候选化合物的性能优于净电荷为0的单羧酸衍生物,因此在临床应用之前有必要对这类支架进行进一步评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Pharmaceutics
Molecular Pharmaceutics 医学-药学
CiteScore
8.00
自引率
6.10%
发文量
391
审稿时长
2 months
期刊介绍: Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信